N1,N4-Bis(3-(1H-benzo[d]imidazol-2-yl)phenyl)terephthalamide

Catalog No. :
ACWCBT828
CAS No. :
500538-94-3
Molecular Formula :
C34H24N6O2
Molecular Weight :
548.61

IUPAC Name:N1,N4-bis(3-(1H-benzo[d]imidazol-2-yl)phenyl)terephthalamide

N1,N4-Bis(3-(1H-benzo[d]imidazol-2-yl)phenyl)terephthalamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg98%$122.00Login to see priceInquiryInquiry
10mg98%$211.00Login to see priceInquiryInquiry
25mg98%$495.00Login to see priceInquiryInquiry
50mg98%$852.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN1,N4-Bis(3-(1H-benzo[d]imidazol-2-yl)phenyl)terephthalamide
IUPAC NameN1,N4-bis(3-(1H-benzo[d]imidazol-2-yl)phenyl)terephthalamide
Molecular FormulaC34H24N6O2
Molecular Weight548.61
SMILESO=C(NC1=CC=CC(C2=NC3=CC=CC=C3N2)=C1)C4=CC=C(C(NC5=CC=CC(C6=NC7=CC=CC=C7N6)=C5)=O)C=C4
InChI KeyWSXIJTIFOWCMIQ-UHFFFAOYSA-N
SynonymCS-0022621 | N~1~,N~4~-Bis(3-(1H-benzimidazol-2-yl)phenyl)terephthalamide | BDBM47836 | HY-102019 | DTXSID101164321 | N1,N4-bis[3-(1H-benzimidazol-2-yl)phenyl]benzene-1,4-dicarboxamide | 1-N,4-dicarboxamide | AKOS005166265 | HMS2858D17 | N,N'-bis[3-(1H-be
CAS No.500538-94-3
PubChem CID247228

Synthetic Route by SureRoute

1. ACWCBT828 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACZSQP109 route compound structure diagram
    ACZSQP1097596-74-9 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWCBT828 route product structure diagram
    ACWCBT828500538-94-3
Inquiry

2. ACWCBT828 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACZSQP109 route compound structure diagram
    ACZSQP1097596-74-9 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWCBT828 route product structure diagram
    ACWCBT828500538-94-3
Inquiry

Comments (0)